The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM D

OMB APPROVAL		
OMB Number:	3235-0076	
Estimated average burden		
hours per response:	4.00	

## **Notice of Exempt Offering of Securities**

1. Issuer's Identity			
•	Describeres		
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001541157			X Corporation
Name of Issuer			Limited Partnership
Morria Biopharmaceuticals PLC			Limited Liability Company
Jurisdiction of Incorporation/Org	anization		
UNITED KINGDOM			General Partnership
Year of Incorporation/Organizati	on		Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Spe	cify Year)		
Yet to Be Formed			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
Morria Biopharmaceuticals PLC			
Street Address 1		Street Address 2	
53 DAVIES STREET		Otroot / taarcoo 2	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
LONDON	UNITED KINGDOM	W1K 5JH	+44-207-152-6341
D I ( I D			
3. Related Persons			
Last Name	First Name		Middle Name
Cohen	Yuval		
Street Address 1	Street Address 2		
c/o Morria Biopharmaceuticals Ple	53 Davies Street		
City	State/Province/Co	untry	ZIP/PostalCode
London	UNITED KINGDOM	1	W1K 5JH
Relationship: X Executive Office	cer X Director Promoter		
Clarification of Response (if Nec	0000m/\		
Cialification of Response (if Nec	essaiy).		
Last Name	First Name		Middle Name
Elefant	Dov		
Street Address 1	Street Address 2		
c/o Morria Biopharmaceuticals Ple			
City	State/Province/Co	untry	ZIP/PostalCode
London	UNITED KINGDOM	1	W1K 5JH
Relationship: X Executive Office	cer Director Promoter		
Clarification of Response (if Nec	essary):		
Last Name	First Name		Middle Name
Yedgar	Saul		
Street Address 1	Street Address 2		
Department of Biochemistry	Hebrew University -	Hadassah Med School	

City	State/Province/Country	ZIP/PostalCode	
Jerusalem	ISRAEL	91120	
Relationship: X Executive Officer X Dir	ector Promoter		
	_		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Cohen	Mark		
Street Address 1	Street Address 2		
Chairman, Pearl Cohen Zedek Latzer, LLP	1500 Broadway, 12th Floor		
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10036	
Relationship: Executive Officer X Direction	ector Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Nesses	
Last Name	First Name	Middle Name	
Lau	Johnson		
Street Address 1	Street Address 2		
701 Ellicott Street	0	71D/D 1 10 1	
City	State/Province/Country	ZIP/PostalCode	
Buffalo	NEW YORK	14203	
Relationship: Executive Officer X Direction	ector Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Raday	Gilead		
Street Address 1	Street Address 2		
4025 Middlefield Road			
City	State/Province/Country	ZIP/PostalCode	
Palo Alto	CALIFORNIA	94303	
Relationship: Executive Officer X Direction			
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Eiran	Amos		
Street Address 1	Street Address 2		
2 Avner Street			
City	State/Province/Country	ZIP/PostalCode	
Herzeliya	ISRAEL	46662	
Relationship: Executive Officer X Direction	_		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
	Alan	MIGGIC NAITIE	
Harris Street Address 1			
Street Address 1	Street Address 2		
190 E. 72nd Street, #32C	State/Dravings/Country	ZID/DestalCed-	
City	State/Province/Country	ZIP/PostalCode	
New York	NEW YORK	10021	
Relationship: X Executive Officer Direction	ector Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Sidransky	David		
Street Address 1	Street Address 2		

Ha'Ari 39			
City	State/Province/Country	ZIP/PostalCode	
Rehovot	ISRAEL	7637239	
Relationship: Executive Officer X Direction	ctor Promoter		
Clarification of Response (if Necessary):			
4. Industry Group			
□ <b>.</b>	Health Care		
Agriculture	X Biotechnology	Retailing	
Banking & Financial Services		Restaurants	
Commercial Banking	Health Insurance	Technology	
Insurance	Hospitals & Physicians	Computers	
Investing	Pharmaceuticals	Telecommunications	
Investment Banking	Other Health Care		
Pooled Investment Fund	$\neg$	Other Technology	
Is the issuer registered as an investment company under	Manufacturing Real Estate	Travel	
the Investment Company		Airlines & Airports	
Act of 1940?	Commercial	Lodging & Conventions	
YesNo	Construction	Tourism & Travel Services	
Other Banking & Financial Services	REITS & Finance	Other Travel	
Business Services	Residential		
Energy	Other Real Estate	Other	
Coal Mining	Other Real Estate		
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
5. Issuer Size			
Revenue Range OR	Aggregate Net Asset V	alue Range	_
X No Revenues	No Aggregate Net A	_	
\$1 - \$1,000,000	\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,00	0,000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,0		
\$25,000,001 -	\$50,000,001 - \$100,		
\$100,000,000			
Over \$100,000,000	Over \$100,000,000		
Decline to Disclose	Decline to Disclose		
Not Applicable	Not Applicable		
6. Federal Exemption(s) and Exclusion(s	s) Claimed (select all that apply)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505		
Rule 504 (b)(1)(i)	X Rule 506		
Rule 504 (b)(1)(ii)	Securities Act Sect	ion 4(5)	
Rule 504 (b)(1)(iii)	Investment Compar	ny Act Section 3(c)	

Section	3(c)(1) Section 3(c)(9)	
Section	3(c)(2) Section 3(c)(10)	
Section	3(c)(3) Section 3(c)(11)	
Section	3(c)(4) Section 3(c)(12)	
Section		
Section		
Section	3(c)(7)	
7. Type of Filing		
X New Notice Date of First Sale 2013-01-18 First Sale Yet	o Occur	
Amendment		
8. Duration of Offering		
o. Baration of Officing		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
X Equity	Pooled Investment Fund Interests	
Debt	Tenant-in-Common Securities	
X Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or C	Other (describe)	
Right to Acquire Security	LI ' '	
10. Business Combination Transaction		
Is this offering being made in connection with a business combinate merger, acquisition or exchange offer?	ation transaction, such as a Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor CO LICD		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number None	
Garden State Securities, Inc.	10083	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number $\overline{\mathbf{X}}$ None	
None	None	
Street Address 1 328 NEWMAN SPRINGS ROAD	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
RED BANK	NEW JERSEY	07701
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
MICHIGAN NEW YORK UTAH VIRGINIA		
13. Offering and Sales Amounts		

Total Offering Amount \$10,000,000 USD or Indefinite
Total Amount Sold \$931,000 USD
Total Remaining to be Sold \$9,069,000 USD or Indefinite
Clarification of Response (if Necessary):
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions $74,480$ USD $\overline{\mathrm{X}}$ Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
Garden State Securities, Inc. served as placement agent for the Issuer and received warrants to purchase 50,235 shares at \$2 per share, \$5,000 as reimbursement of legal fees, and \$74,480 in sales commissions.
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### **Terms of Submission**

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Morria Biopharmaceuticals PLC	/s/ Dov Elefant	Dov Elefant	Chief Financial Officer	2013-02-01

### displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.